Induction of vascular endothelial growth factor-A 165a in human retinal and endothelial cells in response to glyoxal.
Henning MorawietzAnnika FrenzelAlice MietingWinfried GoettschMonika ValtinkCora RoehleckeJózsef JászaiRichard H W FunkKlio A BeckerKatrin EngelmannPublished in: Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy (2022)
Low-density lipoprotein (LDL) apheresis is effective and safe for patients with diabetes, proteinuria, and dyslipidemia. Diabetes mellitus is accompanied by ocular microvascular complications like retinal neovascularization or diabetic macular edema. These are leading causes of blindness and can be mediated by abnormal vessel growth and increased vascular permeability due to elevated levels of vascular endothelial growth factor (VEGF) in diabetic patients. In this study, we established methods to study the expression of different VEGF isoforms in human retinal and endothelial cells. The VEGF-A 165a isoform is much higher expressed in retinal cells, compared to endothelial cells. Stimulation with glyoxal as a model of oxidative stress under diabetic conditions lead to a pronounced induction of VEGF-A 165a in human retinal and endothelial cells. These data suggest that diabetes and oxidative stress induce VEGF-A isoforms which could be relevant in regulating the ingrowths of novel blood vessels into the retina in diabetic patients.
Keyphrases
- endothelial cells
- vascular endothelial growth factor
- diabetic retinopathy
- optical coherence tomography
- optic nerve
- high glucose
- oxidative stress
- induced apoptosis
- type diabetes
- low density lipoprotein
- dna damage
- cardiovascular disease
- poor prognosis
- ischemia reperfusion injury
- machine learning
- long non coding rna
- glycemic control
- big data
- cell death
- signaling pathway
- artificial intelligence